Cardio Diagnostics (CDIO) vs Trinity Biotech (TRIB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cardio Diagnostics is the larger company by market cap ($5.8 million vs $5.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CDIO | TRIB |
|---|---|---|
| Share price | $1.96 | $6.75 |
| Market cap | $5.80M | $5.49M |
| 1-day change | -2.00% | -5.59% |
| EPS (TTM) | $-2.91 | $-56.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.91 | $52.50 |
| 52-week low | $0.97 | $5.01 |
| Distance from 52-week high | -75.22% | -87.14% |
| Average volume | 55.78K | 21.83K |
| Shares outstanding | 2.96M | 813.13K |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
CDIO vs TRIB FAQ
Which is bigger, Cardio Diagnostics or Trinity Biotech?
Cardio Diagnostics (CDIO) is larger, with a market capitalization of $5.80M compared with $5.49M for Trinity Biotech (TRIB).
Are Cardio Diagnostics and Trinity Biotech in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.